Skip to content
POM-V Prescription Required Companion Animal

Thyroxanil 200 Microgram Tablets for Dogs and Cats

Active ingredient: L Thyroxine Sodium

Form

Tablet

Species

Cats Dogs

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/4031

What it's used for

Treatment of primary and secondary hypothyroidism.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for L Thyroxine Sodium

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Thyroxanil 200 Microgram Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Treatment of primary and secondary hypothyroidism.
Oral use.
The recommended starting dose for dogs and cats is 20 µg levothyroxine sodium per
kg body weight per day given as a single daily dose or in two equally divided doses.
Because of variability in absorption and metabolism, the dosage may require
alterations before a complete clinical response is observed. The initial dosage and
frequency of administration are merely a starting point. Therapy has to be highly
individualised and tailored to the requirements of the individual animal especially for
cats and small dogs. See also section 4.5 ‘Special precautions for use in animals’ for
use in animals <2.5 kg. The dose should be adjusted based on clinical response and
plasma thyroxine levels. In the dog and cat, absorption of levothyroxine sodium may
be affected by the presence of food. The timing of treatment and its relation to
feeding should therefore be kept consistent from day to day. To adequately monitor
therapy, trough values (just prior to treatment) and peak values (about four hours
after dosing) of plasma T4 can be measured. In adequately dosed animals peak
plasma concentration of T4 should be in the high-normal range (approximately 30 to
47 nmol/l) and trough values should be above approximately 19 nmol/l. If T4 levels
are outside this range the levothyroxine sodium dose can be adjusted in appropriate
increments until the patient is clinically euthyroid and serum T4 is within the reference
range. The 200 µg tablets enable adjustment of the levothyroxine dose by 50 µg
increments per animal and 600 µg tablets enable adjustment of the levothyroxine
dose by 150 µg increments per animal. Plasma T4 levels can be retested two weeks
after change of dosage, but clinical improvement is an equally important factor in

Revised: February 2021
AN: 00902/2020Page 4 of 7
determining individual dosage and this will take four to eight weeks. When the
optimum replacement dose has been attained, clinical and biochemical monitoring
may be performed every 6 – 12 months.
The following table is intended as a guide to dispensing the product at approximately
the standard
day.
Administration once
daily
Administration twice
dailyBody weight
Thyroxanil
200 µg
Thyroxanil
600 µg
Actual
dose
per kg
(μg)
Thyroxanil
200 µg
Thyroxanil
600 µg
>2.5 kg – 5
kg
20 - 10->5 kg – 7.5
kg
20 - 13.3>7.5 kg – 10
kg or
20 - 15>10 kg – 12.5
kg
20 - 16>12.5 kg – 15
kg or
24 - 20
or
>15 kg – 17.5
kg
23.3 - 20>17.5 kg – 20
kg
22.9 - 20>20 kg – 22.5
kg or
22.5 - 20>22.5 kg – 25
kg
22.2 - 20>25 kg – 30
kg or
24 - 20
or
>30 kg – 40
kg and
26.7 - 20
>40 kg – 50
kg
and
25 - 20>50 kg – 60
kg
24 - 20
= ¼ Tablet = ½ Tablet = ¾ Tablet = 1 Tablet
Tablets can be divided into halves or quarters to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.

Revised: February 2021
AN: 00902/2020Page 5 of 7
Halves: press down with your thumbs on both sides of the tablet.
Quarters: press down with your thumb in the middle of the tablet.
Do not use in dogs and cats suffering from uncorrected adrenal insufficiency.
Do not use in cases of known hypersensitivity to levothyroxine sodium or to any of
the excipients.
An exacerbation of skin symptoms, with increased pruritus due to shedding of the old
epithelial cells, can occur initially. Pruritus and desquamation have been reported
very rarely in spontaneous reports.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
The diagnosis of hypothyroidism should be confirmed with appropriate tests.

Special precautions for use in animals

Revised: February 2021
AN: 00902/2020Page 2 of 7
A sudden increase in demand for oxygen delivery to peripheral tissues, plus the
chronotropic effects of levothyroxine sodium, may place undue stress on a poorly
functioning heart, causing decompensation and signs of congestive heart failure.
Hypothyroid animals with concurrent hypoadrenocorticism have a decreased ability to
metabolise levothyroxine sodium and therefore an increased risk of thyrotoxicosis.
These animals should be stabilised with glucocorticoid and mineralocorticoid
treatment prior to treatment with levothyroxine sodium to avoid precipitating a
hypoadrenocortical crisis. After this, thyroid tests should be repeated, then gradual
introduction of levothyroxine is recommended (starting with 25% of the normal dose
and increasing by 25% increments every fortnight until optimal stabilisation is
achieved). Gradual introduction of therapy is also recommended for animals with
other concurrent illnesses; particularly in animals with cardiac disease, diabetes
mellitus and renal or hepatic dysfunction.
Owing to limitations in size and divisibility of the tablets, it may not be possible to
optimally dose animals weighing less than 2.5 kg. Therefore use of the product in
these animals should be based on a careful benefit-risk assessment by the
responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This product contains a high concentration of levothyroxine sodium and may be
harmful when ingested, particularly for children. Pregnant women should handle this
veterinary medicinal product with caution. Levothyroxine may cause hypersensitivity
(allergy) following ingestion. Avoid skin contact with this product if you know you are
sensitized. Wash hands after handling the tablets. In the case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to the
physician.
Any unused tablet portion(s) should be returned to the open blister, stored out of the
sight and reach of children and always be used at the next administration.
A variety of drugs may impair plasma or tissue binding of the thyroid hormones or
alter thyroid hormone metabolism (e.g. barbiturates, antacids, anabolic steroids,
diazepam, furosemide, mitotane, phenylbutazone, phenytoin, propranolol, large
doses of salicylates and sulphonamides). When treating animals that are receiving
concurrent medication the properties of these drugs should be taken into
consideration.
Oestrogens may increase thyroid requirements.
Ketamine may cause tachycardia and hypertension when used in patients receiving
thyroid hormones.
The effect of catecholamines and sympathomimetics is increased by levothyroxine.
An increase in the dosage of digitalis may be necessary in a patient that had
previously compensated congestive heart failure and that is placed on thyroid
hormone supplementation. Following treatment of hypothyroidism in patients with
concurrent diabetes, careful monitoring of diabetic control is recommended.
Most patients on chronic high-dose, daily glucocorticoid therapy will have very low or
undetectable serum T4 concentrations, as well as subnormal T3 values.
Do not store above 25°C.
Keep the blisters in the outer carton in order to protect from light.
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.